These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32205172)

  • 1. An Unusual Gastric Lesion during Chemotherapy for Pancreatic Cancer.
    Hattori A; Hamada Y; Kawabata H
    Gastroenterology; 2020 Jul; 159(1):45-47. PubMed ID: 32205172
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report.
    Choi SJ; Kim HJ; Kim JS; Bak YT; Kim JS
    BMC Cancer; 2016 Aug; 16():588. PubMed ID: 27484349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer.
    Graziani C; Hegde S; Saif MW
    Anticancer Res; 2014 Dec; 34(12):7339-43. PubMed ID: 25503169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer.
    Takatori K; Terashima K; Yoshida R; Horai A; Satake S; Ose T; Kitajima N; Kinoshita Y; Demizu Y; Fuwa N
    J Gastroenterol; 2014 Jun; 49(6):1074-80. PubMed ID: 23846547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
    Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
    Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy.
    Nakamura A; Shibuya K; Matsuo Y; Nakamura M; Shiinoki T; Mizowaki T; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):369-75. PubMed ID: 22381898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine-induced radiation recall myositis in a patient with dermatomyositis.
    Graf SW; Limaye VS; Cleland LG
    Int J Rheum Dis; 2014 Jul; 17(6):696-7. PubMed ID: 24283707
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful neoadjuvant treatment with radiochemotherapy and systemic chemotherapy for the locally advanced pancreatic head cancer: report of a case.
    Masui T; Doi R; Ogawa K; Kami K; Machimoto T; Seo S; Kawaguchi Y; Egawa H; Matsugu Y; Uemoto S
    Hepatogastroenterology; 2011; 58(110-111):1809-13. PubMed ID: 22086705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine-related radiation recall in a patient with pancreatic cancer.
    Saif MW; Sellers S; Russo S
    Anticancer Drugs; 2006 Jan; 17(1):107-11. PubMed ID: 16317298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
    Gurka MK; Collins SP; Slack R; Tse G; Charabaty A; Ley L; Berzcel L; Lei S; Suy S; Haddad N; Jha R; Johnson CD; Jackson P; Marshall JL; Pishvaian MJ
    Radiat Oncol; 2013 Mar; 8():44. PubMed ID: 23452509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma.
    Takeda Y; Nakamori S; Eguchi H; Kobayashi S; Marubashi S; Tanemura M; Konishi K; Yoshioka Y; Umeshita K; Mori M; Doki Y; Nagano H
    Jpn J Clin Oncol; 2014 Dec; 44(12):1172-80. PubMed ID: 25425728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.
    Shaikh T; Wang LS; Egleston B; Burki M; Hoffman JP; Cohen SJ; Meyer JE
    Am J Clin Oncol; 2018 Jan; 41(1):59-64. PubMed ID: 26325492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An example case that chemoradiotherapy was succeeded for unresectable pancreas cancer].
    Kawashima Y; Horiuchi H; Akashi M; Nogita H; Kitasato Y; Akasu G; Mikagi K; Kawahara R; Ishikawa H; Hisaka T; Kinoshita H; Shirouzu K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2155-7. PubMed ID: 22202314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
    Abrams RA; Winter KA; Regine WF; Safran H; Hoffman JP; Lustig R; Konski AA; Benson AB; Macdonald JS; Rich TA; Willett CG
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):809-16. PubMed ID: 21277694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy.
    Kamachi H; Tsuruga Y; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamiyama T; Katoh N; Taketomi A
    In Vivo; 2018; 32(5):1183-1191. PubMed ID: 30150442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine-based concurrent chemoradiotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
    Wang BH; Cao WM; Yu J; Wang XL
    Asian Pac J Cancer Prev; 2012; 13(5):2129-32. PubMed ID: 22901181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Two Case Reports of Chemotherapy-Induced Radiation Myositis].
    Nishibuchi I; Wadasaki K
    Gan To Kagaku Ryoho; 2018 Jun; 45(6):1005-1007. PubMed ID: 30026433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Case.
    Fujiwara Y; Shiba H; Uwagawa T; Futagawa Y; Misawa T; Yanaga K
    Int Surg; 2015 Feb; 100(2):287-91. PubMed ID: 25692432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
    World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer?
    Zhang X; Huang HJ; Feng D; Yang DJ; Wang CM; Cai QP
    World J Gastroenterol; 2014 Dec; 20(46):17648-55. PubMed ID: 25516680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.